Melanie Cerullo is chief quality officer at Kindeva.

Melanie Cerullo

Pharmaceutical factory woman worker in protective clothing operating production line in sterile environment | Image Credit: ©Ivan Traimak -stock.adobe.com. Background: Canva

The 2023 revision of Annex 1 of the European Union’s good manufacturing practice (GMP) guidelines

 represents a fundamental shift in expectations for sterile manufacturing. Regulators now expect a comprehensive, risk-based contamination control strategy (CCS) that is actively managed across the product life cycle. It requires manufacturers to demonstrate how sterility assurance is designed, governed, executed, monitored, and continuously improved.

For pharmaceutical and biotechnology companies, particularly for those with lean internal manufacturing capabilities or evolving sterile pipelines, Annex 1 raises the bar for oversight, data integration, and risk management. Meeting these expectations depends on technical compliance supported by disciplined execution, mature systems, and a clear operating model for contamination control.

In this article, the author explores how the revised European Union GMP Annex 1 is reshaping expectations and how collaboration with expert sterile manufacturing contract development and manufacturing organizations (CDMOs) can help pharmaceutical and biotechnology companies ensure the highest level of sterility assurance for patient safety.

How Has Annex 1 Changed the Mindset for Sterility Assurance?

The revised Annex 1 marks a deliberate move from prescriptive requirements to a performance-based framework centered on prevention. Manufacturers are expected to demonstrate that controls are scientifically justified, integrated across systems, and routinely evaluated for effectiveness.

To meet these requirements, a compliant CCS must explain how facilities, equipment, utilities, materials, personnel, and processes work together to control risk. It must also demonstrate how risks are reassessed as products, volumes, and technologies change, which can be challenging for sponsor companies new to sterile manufacturing or to managing complex pipelines.

These expectations elevate contamination control from a procedural requirement to a strategic discipline. This shift connects quality, engineering, microbiology, and operations through shared accountability and data-driven decision-making.

Sponsors face the following key challenges as they adapt to Annex 1’s expanded expectations:

Life cycle continuity. Contamination control must be maintained from early clinical manufacture through commercial production. For companies outsourcing development, this means ensuring continuity of risk management and documentation across multiple external partners and sites.

Limited internal sterile capability. Many organizations rely on CDMOs for aseptic capability and may lack the internal expertise or capacity to redesign processes, retrain staff, or upgrade facilities for Annex 1 compliance across their portfolio.

Fragmented data systems. Effective CCS management depends on comprehensive and integrated data. Disconnected systems limit visibility and make trend analysis, which is paramount for an effective CCS, more difficult.

Resource demands. Maintaining CCS discipline over time requires sustained cross-functional engagement that can strain internal teams.

These realities are driving many companies to seek manufacturing partners that can provide both execution capability and structured contamination control frameworks.

How Can External Expertise Be Leveraged for Contamination Control?

External partners specializing in sterile manufacturing can provide both the depth and breadth of experience required to successfully implement Annex 1. By operating across multiple delivery platforms, including injectables, pulmonary, nasal, and dermal systems, CDMO partners must continuously refine their understanding of contamination risks and controls—a distinct benefit for sponsors navigating sterility challenges. Each project adds to a collective knowledge base that can be applied across modalities, accelerating learning and driving continuous improvement in sterility assurance.

A CDMO with sterile fill-finish expertise and facilities can help sponsors meet Annex 1 expectations in the following ways:

Establishing and maintaining a harmonized CCS framework that aligns risk assessment, monitoring, and control activities across all stages of development and commercial stages.

Providing facility designs, environmental monitoring programs, and aseptic processes aligned with global regulatory expectations.

Leveraging digital quality systems to integrate data from deviations, corrective and preventive action (CAPA), change control, and environmental monitoring into a unified risk profile.

Embedding contamination control culture through training, behavioral standards, and management oversight.

Enabling transparency through shared access to CCS-relevant data, supporting sponsor oversight, and regulatory confidence.

When executed well, this approach reduces uncertainty, supports inspection readiness, and strengthens sterility assurance.

How Is a Living Contamination Control Strategy Designed?

A compliant CCS must function as an operational system, not a static reference. Controls should be actively managed, monitored, and adjusted based on risk and performance. Mature organizations maintain risk registers that link each process step to potential contamination sources and defined control measures. These registers are reviewed routinely using data from environmental monitoring, process simulations, deviations, and change management.

As products scale or processes evolve, controls must evolve with them. Cross-functional teams spanning engineering, microbiology, quality, and operations are crucial to help anticipate change and prevent failures.

Digital infrastructure supports this approach by connecting quality management system (QMS) and manufacturing execution system data for trending across batches, shifts, and campaigns, enabling earlier identification of risk signals. Dashboards and automated alerts support timely decision-making and documented effectiveness reviews.

Advanced analytics and predictive tools may further enhance this capability when used to inform scientific judgment.

For sponsors, partnering with a CDMO that already has this infrastructure in place can dramatically shorten implementation timelines and help reduce quality uncertainties.

Annex 1 places structured risk management at the center of contamination control. For outsourced manufacturing, this requires a common methodology and language between the sponsor and CDMO.

Standardized tools, such as failure mode and effects analysis, support consistent risk identification, evaluation, and mitigation. Transparency into how risks are assessed and controlled allows sponsors to demonstrate appropriate oversight while leveraging the CDMO’s operational expertise.

However, even with strong systems, human behavior remains a critical variable. Disciplined execution, strong training, and clear expectations help control risk.

Organizations with mature contamination control cultures reinforce 3 fundamentals:

Patient centricity is a clear understanding that every action directly affects patient safety.

Operational excellence is a commitment to performing each task consistently and seeking continual improvement.

Knowledge and risk management is the habit of questioning, learning, and sharing insights to prevent recurrence.

. Annex 1 explicitly links contamination control to the product life cycle. Early engagement during development enables risks to be addressed upstream before qualification and scale-up. As programs mature, commercial data should be fed back into the CCS to refine controls and confirm robustness.

Digital collaboration tools, including shared QMS platforms and secure data portals, support effective oversight without slowing execution. Regular joint reviews ensure alignment and timely decision-making.

Continuous Improvement and Turning Insights Into Action

To remain effective across the product life cycle, a CCS must be actively improved using data that is collected, analyzed, and acted upon systematically. When sponsors and CDMOs take a proactive approach to data, continuous improvement becomes a natural outcome.

Harmonized key performance indicators (KPIs) such as environmental monitoring trends, aseptic process simulation success rates, deviation recurrence, and CAPA timeliness create a shared language for quality. Standardizing these metrics across sites enables meaningful benchmarking, supports early recognition of emerging risks, and highlights areas of excellence that can be replicated across programs.

To translate KPIs into meaningful change, sponsors and CDMOs need structured, collaborative reviews that turn data into action. Regular cross-functional CCS discussions can transform learnings from individual projects into enterprise-wide improvements. This approach promotes transparency, strengthens partnerships, and creates a cycle of knowledge sharing that benefits every product and every patient.

Annex 1 sets a higher standard for sterility assurance, one that is proactive, science-based, and continuously managed. Organizations that treat the CCS as a static compliance document will struggle to meet regulatory expectations.

Experienced sterile manufacturing partners can accelerate Annex 1 readiness by providing disciplined frameworks, integrated data systems, and operational expertise. The most effective partnerships treat contamination control as a shared responsibility supported by active risk management.

When this approach is embedded, Annex 1 drives stronger processes, safer products, and sustained regulatory confidence, supporting safe and consistent manufacturing for the people who rely on these medicines.

Annex 1 Revision - Manufacture of Sterile Medicinal Products. The Rules Governing Medicinal Products in the European Union Volume 4 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. European Commission. August 2022. Accessed March 25, 2026. 

https://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_en?filename=20220825_gmp-an1_en_0.pdf

Melanie Cerullo, Chief Quality Officer, Kindeva

Articles

The revised EU GMP Annex 1 elevates sterile manufacturing expectations by requiring a science-based, prevention-focused contamination control strategy that is actively governed and improved throughout the product life cycle. Sponsors, especially those outsourcing aseptic operations, must demonstrate integrated risk management across facilities, processes, personnel, and data systems, despite common constraints in internal expertise, resourcing, and system fragmentation. Mature sterile CDMOs can accelerate readiness via harmonized CCS frameworks, digital quality integration, robust monitoring and trending, and culture-setting training and oversight that strengthen inspection readiness and patient safety.

Contract development and manufacturing organizations can assist the sponsor company in ensuring sterility assurance in alignment with the EU’s Annex 1 guidelines.